CU20210061A7 - Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer - Google Patents

Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer

Info

Publication number
CU20210061A7
CU20210061A7 CU2021000061A CU20210061A CU20210061A7 CU 20210061 A7 CU20210061 A7 CU 20210061A7 CU 2021000061 A CU2021000061 A CU 2021000061A CU 20210061 A CU20210061 A CU 20210061A CU 20210061 A7 CU20210061 A7 CU 20210061A7
Authority
CU
Cuba
Prior art keywords
domain
alpha
vaccine composition
mica
cancer
Prior art date
Application number
CU2021000061A
Other languages
English (en)
Inventor
Soumya Badrinath
Kai Wucherpfenning
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of CU20210061A7 publication Critical patent/CU20210061A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

<p>La presente invención proporciona una composición de vacuna que comprende, como un componente inmunogénico, un péptido que comprende o consiste de un dominio alfa 3 de MIC, en donde el péptido comprende o consiste de la secuencia de aminoácidos de SEQ ID NO: 3 o SEQ ID NO: 4 o una secuencia que es al menos 90 porciento idéntica a las mismas. Esta composición de vacuna provoca una respuesta inmune contra el dominio alfa 3 de MIC.</p>
CU2021000061A 2015-12-04 2016-12-05 Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer CU20210061A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562263377P 2015-12-04 2015-12-04
US201662422454P 2016-11-15 2016-11-15
PCT/US2016/064969 WO2017096374A1 (en) 2015-12-04 2016-12-05 Vaccination with mica/b alpha 3 domain for the treatment of cancer

Publications (1)

Publication Number Publication Date
CU20210061A7 true CU20210061A7 (es) 2022-02-04

Family

ID=57590885

Family Applications (2)

Application Number Title Priority Date Filing Date
CU2018000050A CU24609B1 (es) 2015-12-04 2016-12-05 Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic
CU2021000061A CU20210061A7 (es) 2015-12-04 2016-12-05 Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CU2018000050A CU24609B1 (es) 2015-12-04 2016-12-05 Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic

Country Status (24)

Country Link
US (3) US10993971B2 (es)
EP (1) EP3383426A1 (es)
JP (3) JP7099956B2 (es)
KR (1) KR20180088458A (es)
CN (1) CN108770343A (es)
AU (3) AU2016362597C1 (es)
BR (1) BR112018010705A8 (es)
CA (1) CA3005910A1 (es)
CL (3) CL2018001470A1 (es)
CO (1) CO2018006642A2 (es)
CR (2) CR20180350A (es)
CU (2) CU24609B1 (es)
EA (1) EA201891287A1 (es)
IL (1) IL259490A (es)
MX (2) MX2018006785A (es)
MY (1) MY199248A (es)
NZ (1) NZ742663A (es)
PE (2) PE20230495A1 (es)
PH (1) PH12018501170A1 (es)
RU (2) RU2747296C2 (es)
SG (1) SG11201804597TA (es)
TN (1) TN2018000187A1 (es)
WO (1) WO2017096374A1 (es)
ZA (1) ZA202204223B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112512566A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
BR112020019938A2 (pt) 2018-04-03 2021-01-26 Sanofi polipeptídeos antigênicos de vírus sincicial respiratório
CN112512564A (zh) 2018-04-03 2021-03-16 赛诺菲 铁蛋白蛋白
CA3095174A1 (en) 2018-04-03 2019-10-10 Sanofi Antigenic ospa polypeptides
US20240207385A1 (en) * 2020-02-26 2024-06-27 The Wistar Institute Of Anatomy And Biology Compositions comprising self-assembling vaccines and methods of using the same
CA3184940A1 (en) 2020-07-07 2022-01-13 Jennifer Donglan WU Mic antibodies and binding agents and methods of using the same
CN116396398B (zh) * 2023-01-16 2024-07-16 四川大学 一种实现铁蛋白纳米颗粒可控自组装的方法以及基于该方法搭建的纳米颗粒抗原展示平台
CN121620389A (zh) * 2023-04-28 2026-03-06 先为(海南)生物科技有限公司 一种针对MICA/B靶点的mRNA肿瘤疫苗

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
EP0643559B1 (en) 1992-05-06 1999-04-14 The President And Fellows Of Harvard College Diphtheria toxin receptor-binding region
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
JP4469026B2 (ja) 1996-10-31 2010-05-26 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅの抗原およびワクチン
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
ES2275499T3 (es) 1999-03-19 2007-06-16 Glaxosmithkline Biologicals S.A. Vacuna contra streptococcus pneumoniae.
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
WO2003028632A2 (en) 2001-10-01 2003-04-10 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Development of a preventive vaccine for filovirus infection in primates
US6706305B2 (en) 2001-10-31 2004-03-16 Conagra Foods Inc. Low glycemic index bread
EP1504037B1 (en) 2002-05-10 2009-12-30 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
JP5525689B2 (ja) 2004-11-02 2014-06-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 過剰増殖性障害を処置するための組成物および方法
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
US8110196B2 (en) 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
CA2665090A1 (en) 2006-09-22 2008-03-27 Dana-Farber Cancer Institute, Inc. Methods for treating mica-related disorders
US8182809B1 (en) * 2008-09-08 2012-05-22 University Of Washington Methods for treating cancer by inhibiting MIC shedding
WO2011046842A1 (en) 2009-10-12 2011-04-21 The Regents Of The University Of California Targeted nanoclusters and methods of their use
US8889044B2 (en) 2009-12-18 2014-11-18 Kao Corporation Method for producing mesoporous silica particles
JP5603063B2 (ja) 2009-12-21 2014-10-08 花王株式会社 複合シリカ粒子の製造方法
RU2489169C2 (ru) * 2010-10-12 2013-08-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) Способ лечения онкологических заболеваний
EP2758072A1 (en) * 2011-09-23 2014-07-30 University Of Oslo Vaccibodies targeted to cross-presenting dendritic cells
ES2925654T3 (es) 2011-09-30 2022-10-19 Dana Farber Cancer Inst Inc Péptidos terapéuticos que comprenden anticuerpos que se unen a la secuencia A relacionada con el polipéptido del CMH de clase I (MICA)
EP2812027A1 (en) * 2012-02-07 2014-12-17 Innate Pharma Mica binding agents
CN104244929B (zh) 2012-04-16 2017-04-05 哈佛学院董事会 用于调节免疫反应的介孔二氧化硅组合物
JP6518199B6 (ja) * 2013-03-15 2019-06-12 ノヴェロジックス・バイオテクノロジー，インコーポレーテッド Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体
KR20150130462A (ko) 2013-03-15 2015-11-23 다나-파버 캔서 인스티튜트 인크. 치료 펩티드
WO2015139020A2 (en) * 2014-03-14 2015-09-17 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers

Also Published As

Publication number Publication date
AU2022201940B2 (en) 2025-05-08
CR20180350A (es) 2018-10-02
AU2022201940A1 (en) 2022-04-14
IL259490A (en) 2018-07-31
JP7099956B2 (ja) 2022-07-12
CL2023003217A1 (es) 2024-06-28
BR112018010705A8 (pt) 2019-02-26
BR112018010705A2 (pt) 2018-11-21
EP3383426A1 (en) 2018-10-10
PE20181158A1 (es) 2018-07-19
AU2016362597A1 (en) 2018-06-07
JP2018536002A (ja) 2018-12-06
ZA202204223B (en) 2023-12-20
RU2018123307A (ru) 2020-01-13
JP7564842B2 (ja) 2024-10-09
JP2024177207A (ja) 2024-12-19
MX2022010194A (es) 2022-09-19
CL2021001256A1 (es) 2021-12-31
US20180353581A1 (en) 2018-12-13
CU24609B1 (es) 2022-06-06
RU2747296C2 (ru) 2021-05-04
RU2018123307A3 (es) 2020-04-20
US20210299186A1 (en) 2021-09-30
US20250064863A1 (en) 2025-02-27
PH12018501170A1 (en) 2019-01-21
KR20180088458A (ko) 2018-08-03
CU20180050A7 (es) 2018-11-06
SG11201804597TA (en) 2018-06-28
CO2018006642A2 (es) 2018-07-10
PE20230495A1 (es) 2023-03-23
CN108770343A (zh) 2018-11-06
WO2017096374A1 (en) 2017-06-08
JP2022130623A (ja) 2022-09-06
EA201891287A1 (ru) 2018-11-30
CR20230116A (es) 2023-05-05
AU2016362597B2 (en) 2022-02-17
CA3005910A1 (en) 2017-06-08
TN2018000187A1 (en) 2019-10-04
RU2021109510A (ru) 2021-04-16
NZ742663A (en) 2023-02-24
AU2025213685A1 (en) 2025-08-28
CL2018001470A1 (es) 2018-12-21
MX2018006785A (es) 2018-11-09
US10993971B2 (en) 2021-05-04
MY199248A (en) 2023-10-23
AU2016362597C1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
CU20210061A7 (es) Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer
CY1122142T1 (el) Συνθεσεις που περιλαμβανουν στελεχη του βακτηριου blautia για τη θεραπευτικη αγωγη σπλαγχνικης υπερευαισθησιας
MX2023013140A (es) Vacunas contra el virus de la hepatitis b.
MX2019009361A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
CO2017012454A2 (es) Secuencias de uricasa adecuadas para el tratamiento de hiperuricemia
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
BR112018077188A2 (pt) frutose-6-fosfato-3-epimerase termoestável inovadora e um método para produzir alulose com o uso da mesma
EA202090720A1 (ru) ПРОИЗВОДНЫЕ GalNAc
MX2017001279A (es) Usos y composiciones de la flagelina.
MX2016009625A (es) Proteinas quimericas tipo fosfatasa alcalina.
MX2017007256A (es) Inhibidor de bromodominio como adyuvante en la inmunoterapia contra el cancer.
CO2017005038A2 (es) Composicones y métodos de tratamiento con profármacos de tizoxanida, un análogo o sal de la misma
CL2019001200A1 (es) Vacuna contra el parvovirus porcino y el virus del síndrome respiratorio reproductivo porcino y métodos de producción de esta.
MX383316B (es) Promotor de epitelio del pigmento retinal 65 (rpe65) optimizado y secuencias codificantes.
MA43650B1 (fr) Formulations/compositions comprenant un inhibiteur de btk
MX377211B (es) Composiciones terapéuticas para usarse en el tratamiento del cáncer.
ECSP19026702A (es) Compuestos novedosos para el tratamiento de enfermedades parasitarias
MX2016014633A (es) Nuevos derivados de cath2.
BR112017004893A2 (pt) composições e métodos para o tratamento de lesões cutâneas pré-cancerosas
MY193807A (en) T-cell receptor and uses thereof
MX420767B (es) Proteina de union al factor h modificada
CL2018000726A1 (es) Tratamiento con conjugado syd985 de pacientes con cáncer resistente al tratamiento con t-dm1
MX2018001298A (es) Agente inductor de inmunidad.
BR112018075613A2 (pt) peptídeos para o tratamento de osteoartrite